<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695952</url>
  </required_header>
  <id_info>
    <org_study_id>ICI_Biomarker</org_study_id>
    <nct_id>NCT03695952</nct_id>
  </id_info>
  <brief_title>A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors</brief_title>
  <official_title>A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although immune checkpoint inhibitors including nivolumab and pembrolizumab are now available
      for the management of hepatobiliary cancers in Korea, there is a lack of data for the
      efficacy and safety of these agents in the real-world setting. This study aims to
      prospectively evaluate the efficacy of safety of nivolumab and pembrolizumab against advanced
      hepatocellular carcinoma and biliary tract cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nivolumab 3 mg/kg intravenous every 2 weeks has been recently approved by US FDA for the
      management of patients with sorafenib-failed advanced HCC based on the promising data of
      Checkmate-040 phase I/II study. Although there is a lack of prospective data for
      pembrolizumab in biliary tract cancer except for small phase 1 trial, pembrolizumab is now
      available for use in Korea for the management of advanced biliary tract cancer. Because the
      approval of these agents was based on the small sample size, further prospective evaluation
      of nivolumab or pembrolizumab in patients with hepatobiliary cancer is needed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of complete response and partial response according to the Response Evaluation Criteria in Solid Tumors version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Toxicity of nivolumab or pembrolizumab according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Hepatocellular carcinoma</arm_group_label>
    <description>Hepatocellular carcinoma patients treated with nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary Tract Cancer</arm_group_label>
    <description>Biliary tract cancer patients treated with pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab or pembrolizumab</intervention_name>
    <description>Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks</description>
    <arm_group_label>Biliary Tract Cancer</arm_group_label>
    <arm_group_label>Hepatocellular carcinoma</arm_group_label>
    <other_name>Immune checkpoint inhibitors</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hepatobiliary cancer patients treated with nivolumab or pembrolizumab
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma and gallbladder
             cancer) or hepatocellular carcinoma

          -  Planned immune checkpoint inhibitors including nivolumab or pembrolizumab

          -  Written informed consent

        Exclusion Criteria:

          -  Not available for the treatment with immune checkpoint inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Changhoon Yoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changhoon Yoo, MD</last_name>
    <phone>+82230101727</phone>
    <email>yooc@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhoon Yoo</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changhoon Yoo, MD</last_name>
      <phone>+82230101727</phone>
      <email>yooc@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Changhoon Yoo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

